# EDGAR Filing Document

**Accession Number:** 0001830487
**File Stem:** 0001193125-26-201925
**Filing Date:** 2026-5
**Character Count:** 8610
**Document Hash:** 2f1739864504b06ddd25f1369d1f4401
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-201925.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001193125-26-201925

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260429

**FILED AS OF DATE**: 20260501

**DATE AS OF CHANGE**: 20260501

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lesage Anne
- **CENTRAL INDEX KEY:** 0001973705

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40010
- **FILM NUMBER:** 26934273

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O PHARVARIS N.V.
- **STREET 2:** EMMY NOETHERWEG 2
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 2333 BK
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharvaris N.V.
- **CENTRAL INDEX KEY:** 0001830487
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31 (0)71 203 6410

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharvaris, B.V.
- **DATE OF NAME CHANGE:** 20201029

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lesage Anne<br><sub>(Last) (First) (Middle)</sub><br>1 CRANBERRY HILL SUITE 400<br><sub>(Street)</sub><br>LEXINGTON, MA 02421<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Early Development_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Pharvaris N.V. [ PHVS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-04-29 |  | M<sup>(1)</sup> |  | 3700 | A | $2.59 | 60150 | D |  |
| Common Stock | 2026-04-29 |  | S<sup>(1)</sup> |  | 3700 | D | 30.0758<sup>(2)</sup> | 56450 | D |  |
| Common Stock | 2026-04-30 |  | M<sup>(1)</sup> |  | 3700 | A | $2.59 | 60150 | D |  |
| Common Stock | 2026-04-30 |  | S<sup>(1)</sup> |  | 3700 | D | $30.2558 | 56450 | D |  |
| Common Stock | 2026-04-30 |  | M<sup>(1)</sup> |  | 18000 | A | $8.05 | 74450 | D |  |
| Common Stock | 2026-04-30 |  | S<sup>(1)</sup> |  | 18000 | D | $30.2558 | 56450 | D |  |
| Common Stock | 2026-04-29 |  | S<sup>(3)</sup> |  | 3700 | D | 30.062<sup>(2)</sup> | 153169 | I | By GrayMatters Consulting BV<sup>(4)</sup> |
| Common Stock | 2026-04-30 |  | S<sup>(3)</sup> |  | 19200 | D | 30.2557<sup>(5)</sup> | 133969 | I | By GrayMatters Consulting BV<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $2.59 | 2026-04-29 |  | M<sup>(1)</sup> |  |  | 3700 | <sup>(6)</sup> | 2030-01-01 | Common Stock | 3700 | $0 | 12772 | D |  |
| Stock Option (Right to Buy) | $2.59 | 2026-04-30 |  | M<sup>(1)</sup> |  |  | 3700 | <sup>(6)</sup> | 2030-01-01 | Common Stock | 3700 | $0 | 9072 | D |  |
| Stock Option (Right to Buy) | $8.05 | 2026-04-30 |  | M<sup>(1)</sup> |  |  | 18000 | <sup>(7)</sup> | 2033-04-06 | Common Stock | 18000 | $0 | 82000 | D |  |

---

### Footnotes:

(1) This is a scheduled exercise and sale from 10b5-1 trading plan.

(2) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(3) This is a scheduled sale from 10b5-1 trading plan.

(4) GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

(5) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(6) 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

(7) 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

**Signature:** /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage  
**Date:** 2026-05-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**